PMID-39945396 — Bushi: GLP-1 RA and Suicidal Ideation (Systematic Review + Meta-Analysis)

[DRAFT — authored 2026-04-19. Citation web-verified 2026-04-19 against PubMed. Requires Medical Director content review.]

Citation

Bushi G, Khatib MN, Rohilla S, Singh MP, Uniyal N, Ballal S, Bansal P, Bhopte K, Gupta M, Gaidhane AM, Tomar BS, Ashraf A, Ravi Kumar M, Chauhan AS, Sah S, Abu Serhan H, Shabil M. Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis. Diabetes/Metabolism Research and Reviews. 2025;41(2):e70037. doi: 10.1002/dmrr.70037. PMID: 39945396. PMCID: PMC11823376.

External URL: DOI resolver

Phase 1 manifest note: This paper was listed in the manifest as "suicidal ideation meta-analysis 2024" with identifier PMC11823376. Web-verification 2026-04-19 confirms the PMCID maps to PMID: 39945396, published February 2025 (not 2024 as the manifest date suggested). Key finding RR 0.568 (95% CI 0.077-4.205) matches manifest.

Study Design

Design: Systematic review and meta-analysis of observational studies
Eligibility: Cohort and case-control studies examining GLP-1 RA use and suicidal ideation, suicide attempts, or completed suicide in adults
Search: PubMed, Embase, Web of Science through September 2024
Guidelines: PRISMA
Studies included for meta-analysis: 4 studies pooled for suicidal outcomes

Key Findings

Pooled relative risk (suicidal outcomes, GLP-1 RA vs non-GLP-1 comparator): RR 0.568 (95% CI 0.077-4.205) — not statistically significant
Heterogeneity: I² = 98% — very high, limiting interpretation of the point estimate
Overall conclusion: No significant association between GLP-1 RA use and increased suicidal ideation or behaviour based on available evidence
Pharmacovigilance-evidence reliance: Several included studies draw on FAERS/VigiBase data — which has known confounding-by-indication issues (depressed patients often receive obesity and diabetes therapy)
Authors' recommendation: Continued clinical monitoring advised, particularly for patients with baseline psychiatric conditions; further long-term safety research warranted

Clinical Relevance

Bushi 2025 provides the quantitative meta-analytic anchor for the clinician statement that "available evidence does not support a causal link between GLP-1 RA therapy and suicidal ideation/behaviour." The null finding aligns with:

The FDA January 2024 Drug Safety Communication preliminary evaluation (REG-FDA-Suicidal-Ideation-Review-2024 – FDA GLP1 Suicidal Ideation Null Finding)
The broader psychiatric-effects systematic review (PMID-41126551 – Psychiatric Effects GLP1 Systematic Review)
The subsequent FDA action requesting removal of suicidal-ideation warnings from GLP-1 RA labeling

Teaching implications:

In Lesson 5.2 mental-health screening, frame the suicidality question as: evidence does not support increased risk; continue clinical monitoring for patients with psychiatric history because overlap between obesity care and mental-health burden is real, not because GLP-1 RAs are a discrete suicidality trigger
High I² means the aggregate is interpreted with appropriate epistemic humility
Baseline PHQ-9 / mood screening at initiation remains clinically reasonable

Limitations (Author-acknowledged)

Only 4 studies pooled for the quantitative synthesis
High heterogeneity (I² = 98%) limits confidence in pooled estimate
Reliance on pharmacovigilance data introduces confounding-by-indication
No dedicated RCT-based meta-analysis for suicidality endpoints (most RCTs not powered for suicidality)
Publication bias possible

Evidence Level

Level II (Oxford CEBM) — systematic review of observational studies with meta-analysis; high heterogeneity moderates confidence.

Linked Peptides

Related Studies

PMID-41126551 – Psychiatric Effects GLP1 Systematic Review (broader psychiatric-effects systematic review companion)
REG-FDA-Suicidal-Ideation-Review-2024 – FDA GLP1 Suicidal Ideation Null Finding (regulatory triangulation)

Orchestrator Notes

Manifest identifier: PMC11823376 → verified PMID: 39945396 via PubMed search.
Publication date: February 2025 (manifest had listed 2024 — corrected).
Companion to the psychiatric-effects systematic review and FDA null finding in Lesson 5.2 mental-health screening narrative.

PMID-39945396 – Suicidal Ideation GLP1 Meta-Analysis